文献速递白血病

迷你Hyper-CVD联合奥加伊妥珠单抗加或不加贝林妥欧单抗治疗老年新诊断费城染色体阴性B细胞急性淋巴细胞白血病:开放标签2期试验长期结果

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
PubMed 文献 · Lancet Haematol · 2023-05-12

本开放标签2期试验在MD安德森癌症中心纳入80例60岁及以上新诊断费城染色体阴性B细胞急性淋巴细胞白血病患者,接受迷你Hyper-CVD联合奥加伊妥珠单抗加或不加贝林妥欧单抗治疗,2年无进展生存率为58.2%,5年无进展生存率为44.0%,方案调整前后中位无进展生存无显著差异(34.7个月 vs 56.4个月,p=0.77)。

要点

  • 老年费城染色体阴性B细胞急性淋巴细胞白血病患者2年无进展生存率为58.2%,5年无进展生存率为44.0%。
  • 方案调整前后中位无进展生存无显著差异(34.7个月 vs 56.4个月,p=0.77)。
  • 最常见3-4级不良事件为血小板减少(78%)和发热性中性粒细胞减少(32%),6例(8%)发生肝窦阻塞综合征。

核心结论

  • 奥加伊妥珠单抗加或不加贝林妥欧单抗联合低强度化疗在老年B细胞急性淋巴细胞白血病患者中显示出有前景的无进展生存活性。
  • 作者认为进一步减轻化疗方案可能改善老年患者的耐受性并维持疗效。

研究设计与样本

  • 开放标签2期试验,在德克萨斯大学MD安德森癌症中心开展,纳入80例60岁及以上新诊断费城染色体阴性B细胞急性淋巴细胞白血病且ECOG体能状态评分≤3的患者。
  • 诱导化疗为迷你Hyper-CVD;奥加伊妥珠单抗在第1-4周期第3天静脉给药,第1周期剂量为1.3-1.8 mg/m2,后续周期(第2-4周期)为1.0-1.3 mg/m2。
  • 维持治疗为减量POMP(6-巯基嘌呤、长春新碱、甲氨蝶呤、泼尼松),持续3年。
  • 自第50例患者起方案修订:奥加伊妥珠单抗分次给药,最大累积剂量2.7 mg/m2(第1周期0.9 mg/m2分次为第2天0.6 mg/m2和第8天0.3 mg/m2;第2-4周期0.6 mg/m2分次为第2天0.3 mg/m2和第8天0.3 mg/m2),随后予贝林妥欧单抗4周期(第5-8周期)。
  • POMP维持缩短至12周期,每3周期POMP后予1周期贝林妥欧单抗持续输注;主要终点为无进展生存,按意向治疗分析。

主要发现

  • 2011年11月11日至2022年3月31日共入组并治疗80例患者(32例女性,48例男性;中位年龄68岁[IQR 63-72]),其中31例在方案修订后治疗。
  • 中位随访92.8个月(IQR 8.8-67.4),2年无进展生存率为58.2%(95%CI 46.7-68.2),5年无进展生存率为44.0%(95%CI 31.2-54.3)。
  • 方案修订前治疗患者中位随访104.4个月(IQR 6.6-89.2),修订后治疗患者中位随访29.7个月(IQR 8.8-41.0),两组中位无进展生存无显著差异(34.7个月[95%CI 15.0-68.3] vs 56.4个月[95%CI 11.3-69.7];p=0.77)。
  • 最常见3-4级事件为血小板减少62例(78%)和发热性中性粒细胞减少26例(32%)。
  • 6例(8%)患者发生肝窦阻塞综合征;8例(10%)死于感染并发症,9例(11%)死于继发性髓系恶性肿瘤相关并发症,4例(5%)死于肝窦阻塞综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse disease biology and their inability to tolerate intensive therapy. We aimed to study the long-term outcomes of inotuzumab ozogamicin with or without blinatumomab in combination with low-intensity chemotherapy in these patients. METHODS: For this open-label phase 2 trial, patients aged 60 years or older with newly diagnosed, Philadelphia-chromosome negative, B-cell acute lymphocytic leukaemia, and an ECOG performance status of 3 or lower were eligible. This study was conducted at the University of Texas MD Anderson Cancer Center. The induction chemotherapy consisted of mini-hyper-CVD and has been published before; inotuzumab ozogamicin was administered intravenously on day 3 of the first four cycles at a dose of 1·3-1·8 mg/m2 in cycle 1, followed by 1·0-1·3 mg/m2 in subsequent cycles (cycles 2-4). Maintenance therapy with dose-reduced POMP (6-mercaptopurine, vincristine, methotrexate, and prednisone) was given for 3 years. From patient 50 onwards, the study protocol was amended to fractionate inotuzumab ozogamicin to a maximum cumulative dose of 2·7 mg/m2 (0·9 mg/m2 during cycle 1 fractionated into 0·6 mg/m2 on day 2 and 0·3 mg/m2 on day 8 of cycle 1, and 0·6 mg/m2 in cycles 2-4 fractionated into 0·3 mg/m2 on day 2 and 0·3 mg/m2 on day 8) followed by blinatumomab for four cycles (cycles 5-8). POMP maintenance was shortened to 12 cycles with one cycle of blinatumomab administered by continuous infusion after every three cycles of POMP. The primary endpoint was progression-free survival and was analysed on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov (NCT01371630) and the present data is from the newly diagnosed, older subgroup of patients treated on the phase 2 portion of this trial; the trial is still enrolling patients. RESULTS: Between Nov 11, 2011, and March 31, 2022, 80 patients were enrolled and treated (32 female and 48 male patients; median age 68 years [IQR 63-72]), 31 of whom were treated after the protocol amendment. With a median follow-up of 92·8 months (IQR 8·8-67·4), the 2-year progression-free survival was 58·2% (95% CI 46·7-68·2) and 5-year progression-free survival was 44·0% (31·2-54·3). At a median follow-up of 104·4 months (IQR 6·6-89·2) for the patients treated before the protocol amendment and 29·7 months (8·8-41·0) for those treated after the protocol amendment, median progression-free survival did not differ significantly between the two groups (34·7 months [95% CI 15·0-68·3] vs 56·4 months [11·3-69·7]; p=0·77). The most common grade 3-4 events were thrombocytopenia in 62 (78%) patients and febrile neutropenia in 26 (32%) patients. Six (8%) patients developed hepatic sinusoidal obstruction syndrome. There were eight (10%) deaths due to infectious complications, nine (11%) from complications related to secondary myeloid malignancy, and four (5%) from sinusoidal obstruction syndrome. INTERPRETATION: Inotuzumab ozogamicin with or without blinatumomab added to low-intensity chemotherapy showed promising activity in terms of progression-free survival in older patients with B-cell acute lymphocytic leukaemia. Further attenuation of the chemotherapy regimen might improve tolerability while maintaining efficacy in older patients. FUNDING: Pfizer and Amgen.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023. PMID: 37187201. doi:10.1016/S2352-3026(23)00073-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。